The following message with updates related to vaccination procedures for faculty and professional staff was sent to the University community:
Summary:
Dear Colleagues,
As we look forward to welcoming our students and colleagues back on campus in the fall, we want to provide you with some additional guidance concerning vaccination against COVID-19. As announced in President Fry'scommunicationon June 10, Drexel University is requiring all current faculty and professional staff to be fully vaccinated against COVID-19 before their return to campus, no later thanAugust 1, 2021,in order to ensure the safety of our community.
We know that safe and effective vaccination has created a path for our campus community to return to normalcy at our University. Over the past few months, thousands of Drexel students, faculty and professional staff have already been fully vaccinated, taking advantage of the many clinics held on campus or the increased availability of vaccine at countless area locations. This communication conveys further guidance concerning the COVID-19 immunization requirement for Drexel faculty and professional staff, as outlined in more detail in the newCOVID-19 Vaccination Policy.
Who Must Be Vaccinated?All faculty and professional staff members are required to receive a COVID-19 vaccine. This requirement involves all individuals in a paid status, including adjunct, casual/per-diem and temporary employees. New employees will receive information regarding the vaccination requirement upon offer of employment.
COVID-19 Immunization Compliance DeadlinesAs previously communicated, all employees are expected to be fully vaccinated before August 1, 2021, which means at least 14 days must have passed since your final dose of vaccine by Aug. 1.
Unvaccinated persons remain at significant risk of serious illness with COVID-19. Those who are granted an exemption, have not received the COVID-19 vaccine, or do not provide required proof of vaccination will be required to comply with the University's health and safety protocols, which include, but are not limited to, daily symptom check-ins via the Drexel Health Checker App, weekly COVID screening tests and wearing masks while in Drexel owned or leased facilities. Failure to comply with these requirements may result in disciplinary action, up to and including termination, as outlined in the policy.
Vaccine ExemptionsYou may apply for an exemption through theCOVID-19 Vaccine Exemption Process. Exemption requests may be granted for medical or religious purposes with approved documentation. Those who do not provide the University with their vaccine information must complete the COVID-19 Vaccine Exemption Process. All who receive an exemption will be enrolled in a mandatory weekly COVID-19 screening program and required to follow additional guidance for your protection, which will be provided at the time exemption is granted.
Providing Proof of VaccinationTo be exempt from weekly testing and additional safety measures at Drexel, it's crucial that you provide proof of vaccination in a timely manner. To do so, you should upload your information along with a picture of your vaccine card to theDrexel Health CheckerApp. If you have yet to download the app, now is the time. Always use your Drexel email to register in the app in the format ofabc12@drexel.eduand avoid using any other email addresses. If you cannot provide your vaccine information via the Health Checker App, please visit Human Resources to provide your vaccine card to complete this process.
On theDrexel Health CheckerApp, after completing your daily check-in, click "More" in the bottom right corner. Select "Vaccine Records". Choose the vaccine type from the drop-down menu, enter the date of your dose and lot number, and then upload a photo of your record. Click "Save." If you receive a two-dose vaccine, you will need to record your first dose before you can add your final dose.The dates you enter must match the dates on the vaccine card.
If you have any questions about the exemption process or the COVID-19 Vaccine Policy, please contact yourHR Business Partner.
Sincerely,
Megan Weyler,Senior Vice President and Chief Human Resources Officer
It's time to mandate COVID-19 vaccines and vaccine passports, according to historian Julian Zelizer. In a column for CNN Opinion, he argues there is a long history of the U.S. requiring Americans to participate in programs aimed at the common good.
Zelizer, professor of history and public affairs at Princeton University, makes his case to host Don Gonyea.
Marines who go maskless on military installations must be prepared to provide proof of COVID-19 vaccination at any time while those found to have lied about their vaccination status for whatever reason may face discipline, according to a recently released Marine Corps message.
Service members and civilian employees who misrepresent their vaccination status may be subject to appropriate adverse administrative or punitive actions, the MARADMIN, released Friday, reads.
The MARADMIN provides clarification to the Department of Defense mask policy released in early May, which allows service members who are fully vaccinated to ditch the mask in almost every circumstance.
Marines who are not fully vaccinated must wear their mask continuously on military installations unless they are alone, eating, drinking, when the mask is required to be lowered for identification, when it is necessary to accommodate a disability or while conducting physical training.
Under the Marine Corps policy, unmasked Marines must be prepared at any time to provide a vaccination card or other health records to prove they are fully vaccinated and authorized to go without a mask.
Supervisors may not inquire about or verify the vaccination status of civilian employees unless there is a reasonable basis to believe the unmasked employee has not been fully vaccinated, based on reliable evidence such as firsthand knowledge of voluntary employee statements, the MARADMIN said.
As of June 30, the Marine Corps was by far the least vaccinated branch in the military, with only 58 percent of Marines vaccinated for COVID-19. Thats far behind the Navy, which leads the Defense Department with a vaccination rate of 77 percent.
Don't miss the top Marine Corps stories, delivered each afternoon
(please select a country) United States United Kingdom Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D'ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe
Subscribe
By giving us your email, you are opting in to the Marine Corps Times Daily News Roundup.
Fridays MARADMIN sets the minimum mask policy for the entire Marine Corps, though individual commanders are allowed to enforce a more restrictive mask policy, according to the MARADMIN.
Marines stationed or deployed overseas must also follow the local laws regarding mask wearing if it is more restrictive than the MARADMIN.
The current Marine Corps policy on the use of masks is limited to Department of Defense facilities, Capt. Andrew Wood, Headquarters Marine Corps spokesman, told Marine Corps Times in an email.
The UK government, which is pushing ahead with its unlocking plan despite strong warnings from experts, has previously said it will mandate shots for care home staff from October.
Not all health care workers are happy with the move. In Italy, several court challenges launched by those who do not want to get vaccinated are being heard this week. In the UK, a petition against the plan to make vaccines compulsory has attracted more than 72,000 signatures.
French President Emmanuel Macron announced on Monday that health care workers, care home employees and those who work with vulnerable and frail patients in France will have to be vaccinated by September 15. Speaking on LCI television following Macron's announcement, health minister Olivier Vran added that unvaccinated health care workers will be banned from going to work and will not be paid after the September deadline.
Macron also hinted at the possibility of making the shot mandatory for everyone if the epidemic worsens. "Depending on the situation, no doubt we will have to ask ourselves the question of mandatory vaccination for all the French," he said. "I have made the choice of trust and I am appealing to all our non-vaccinated countrymen to go and get vaccinated as soon as possible," he added.
Meanwhile, Greek Prime Minister Kyriakos Mitsotakis announced on Monday that vaccinations will be mandatory for nursing home staff, effective immediately. Those who refuse will be suspended from work starting August 16, he said, adding that from September, vaccinations will be compulsory for all health care workers in both public and private sectors.
Mitsotakis said that, starting on Friday and until the end of August, only those who have had the vaccine will be able to visit indoor commercial areas like entertainment centers, bars, theaters and cinemas.
"The country will not shut down again because of the attitude of some," he said, adding that "it is not Greece that is in danger, but the unvaccinated Greeks."
Germany's Chancellor Angela Merkel said Tuesday that her government had decided not to make vaccines compulsory, adding that she believed many more people still wanted to get vaccinated. She said it was up to the authorities to make both information and vaccines more accessible.
She stressed that the country's Covid restrictions would not be lifted until more people have got their shots.
New restrictions across Europe
The moves by France and Greece come as both countries -- and indeed most of Europe -- see a steep increase in cases of the coronavirus caused by the Delta variant. The strain, first identified in India earlier this year, is more transmissible and has spread across the world in recent months.
There are also worries, based on statements from the Israeli government, that existing Covid-19 vaccines may be slightly less effective in preventing all infections caused by the Delta variant, compared to previous strains. The shots do appear to be highly effective in preventing hospitalizations and deaths.
The threat posed by the Delta variant has prompted several European governments to reintroduce restrictions in recent days.
The Netherlands reinstated curbs on nightclubs and restaurants on Friday after seeing a spike in cases. Dutch Prime Minister Mark Rutte apologized for easing the restrictions at the end of June, telling reporters on Monday that it had been an "error in judgment."
The Spanish regions of Valencia and Catalonia have introduced new restrictions on social gatherings and hospitality, while Portugal has reinstated a curfew in some high-risk areas and said it would start requiring tourists to show a negative test or a vaccination certificate in order to stay in hotels.
Even as most of Europe steps on the emergency brake, the UK government remains adamant that it will drop nearly all remaining coronavirus restrictions in England next week.
Prime Minister Boris Jonson confirmed on Monday that the easing will happen despite a steep increase in Covid cases; he admitted this would lead to "more hospitalizations and more deaths from Covid."
He justified the move by pointing to the country's high vaccination rate and added that it was better to open the economy now, when schools are closed for summer holiday and the weather is good.
"If we were now to delay this fourth step [in the reopening process] -- for instance to September or later -- then we would be reopening as the weather gets colder and as the virus acquires a greater natural advantage and when schools are back," he said at a news conference on Monday.
The decision to push ahead comes despite stark warnings from experts and medical professionals. The British Medical Association (BMA), the doctors' trade union, called the government's plan "irresponsible and perilous."
"Scrapping the remaining restrictions next week -- when a significant proportion of the population will not have been fully vaccinated -- will give this deadly virus an opportunity to re-tighten its grip; pushing infection rates up, increasing hospitalizations and people ill with long-Covid, risking new vaccine-resistant variants developing, and putting more lives at unnecessary risk," Dr. Chaand Nagpaul, the BMA's council chair, said in a statement.
The UK has fully vaccinated roughly half of its population, with two thirds of adults now fully vaccinated and 87% having had at least one shot.
CNN's Sarah Dean, Vasco Cotovio, Mick Krever, Sharon Braithwaite, Rob Iddiols and Chris Liakos in London, Nadine Schmidt in Berlin and Barbara Wojazer in Paris contributed to this report.
Posted: Jul 13, 2021 / 03:41 PM HST / Updated: Jul 13, 2021 / 03:41 PM HST
HONOLULU (KHON2) The Honolulu Zoo will be holding another COVID-19 vaccination clinic on Friday, July 16, to administer second doses of the Pfizer vaccine for those who received their first shot on June 26.
Make sure to bring your vaccination card that you received at your first appointment. Individuals ages 12 and older are eligible, and those seeking to get their first shot are also welcome.
The clinic is being conducted as a partnership between the City and County of Honolulu, the state Department of Health and Hawaii Pacific Health (HPH).
HPHs Vax Squad bus will be parked at the zoo on July 16 from 10 a.m. to 3 p.m.
Clients receiving their first dose will be able to choose between the Pfizer (12 years and older) or Johnson & Johnson (18 years and older) COVID-19 vaccine. Click here to pre-register or call (808)-462-5460.
Guests heading to the vaccination site should report toGate 6 on Monsarrat Avenueinstead of the front entrance. Those who get vaccinated will receive complimentary admission to the zoo.
Make sure to bring a photo ID, insurance card and a face mask to be worn at all times.
July 12, 2021 -- Now that the COVID-19 vaccines are available for children ages 12 and older, some divorced parents are facing a challenge: What to do when one parent wants the kids to get the COVID-19 vaccine and the other parent doesnt.
This is the situation facing Michelle Roy-Augustin*, a divorced mom of two sons, ages 12 and 10, who lives in Los Angeles. While her ex-wife wants their 12-year-old-son to get vaccinated right away, Roy-Augustin would rather wait, as some teenagers, albeit rarely, have had heart inflammation after their second dose of the Pfizer or Moderna vaccine, according to the CDC.
Id prefer to wait for there to be a larger sample size of kids getting the vaccine to see if there any other problems, says Roy-Augustin. She says that she and her ex-wife are vaccinated and that the two have never disagreed about any of the other vaccinations their sons have received throughout their childhood.
This is the first time weve disagreed about something like this. Weve been remarkably on the same page with most of our co-parenting decisions -- until now.
Ask divorce attorneys, and theyll tell you that theyve litigated plenty of vaccine issues between ex-spouses lately. But the law is clear: Generally speaking, if the parents arent divorced or living under an order, either parent can give consent for a child to be vaccinated, says Jennifer S. Hargrave, a divorce attorney at Hargrave Family Law in Dallas.
However, once the parents separate and are living under a parenting order [such as a divorce decree], the order will govern which parent has the rights to decide on a childs medical care, including invasive medical procedures such as vaccines, since these puncture the skin, she says.
Depending on the agreement, the right to consent to this sort of procedure requires both parents to agree. In other words, if one parent does not agree to it, then the other parent can stop the child from getting the vaccine, Hargrave says.
The other parent can ask the court to use their judgment to step in and determine whether the child should have the vaccine, she says.
For Roy-Augustin, the to-vaccine-or-not negotiation with her ex-spouse remains ongoing -- and stressful.
I text my ex studies about the side effects of the vaccine, but I doubt she reads them, she says. My ex operates in a state of constant health anxiety. I think shes assuming the schools will mandate the vaccine and then Ill have no choice.
Until the COVID-19 vaccine becomes mandatory -- if that happens, that is -- neither parent should unilaterally sign off on a childs vaccine without the others consent, says Chantelle A. Porter, a family law attorney at A. Traub & Associates in Lombard, IL.
Its best to inform the other parent if you have the sole decision-making responsibility or get consent from your ex-spouse if you have joint decision-making, she says.
If you still cant come to a resolution and you remain in two separate vaccine camps, with neither party even coming close to a concession, you might consider sitting down with your childs pediatrician or a mediator.
I believe it helps for both parents to sit down and have a conversation with an expert about the pros and cons of the vaccine, Porter says. Its also a neutral place where you can raise any concerns you might have.
As for Roy-Augustin, shes hoping to decide by the fall.
"We now have millions of kids getting their second shot, she says. If there arent any problems by October, then I will consider it -- but maybe the J&J and not two shots?
If you and your spouse just cant decide whether or not to have your child vaccinated against COVID-19, you should find a way to discuss this maturely, because this issue isnt going to disappear overnight, says Elizabeth Cohen, PhD, a clinical psychologist in private practice in New York City and author of Light on the Other Side of Divorce.
Below, Cohen, also the self-described Divorce Doctor, suggests three ways to best communicate about this:
1: Separate your feelings for your ex from your co-parenting responsibilities
In fact, your goal should be to rethink the entire way youre talking to your ex, Cohen says. Ask yourself: If I was negotiating with a business partner, how would I approach this situation? she suggests. Yes, your ex is someone you have likely had a long history of not feeling heard. And, yes, this is playing into your conversations with your ex, but you have to put those feelings aside for the sake of resolving this.
2: Stay factual
Avoid saying things like, You always or You never cared about the kids medical stuff before, why do you care now? Cohen suggests.
Instead, be very clear about why you feel like this is the right decision, she says. Again, explain it as if you were talking to a neutral person and take any emotional language out of the discussion.
3: Respect your exs point of view
It can be very challenging, but its very important to come from a place of respect for the other persons opinion, Cohen says.
Remember, your ex feels just as strongly about this as you do, she says. Ask him or her to explain how they came to their decision. Remember: Your underlying anger and resentment towards this person has nothing to do with whether your child should get the vaccine -- or not.
*Name has been changed for privacy purposes
WebMD Health News
Michelle Roy-Augustin, Los Angeles.
Jennifer S. Hargrave, divorce attorney, Hargrave Family Law, Dallas.
Chantelle A. Porter, family law attorney, A. Traub & Associates, Lombard, IL.
Elizabeth Cohen, PhD, clinical psychologist, New York City; author, Light on the Other Side of Divorce.
The Wilkes Health Department announced a schedule of community COVID-19 vaccination clinics.
Meanwhile, 32% (22,201 people) of Wilkes residents are now fully vaccinated and 35% (24,180 people) have received at least one dose of the vaccine. These percentages have been the same for several weeks.
Statewide, 56% of adults are fully vaccinated.
The following COVID-19 community vaccination clinics are open and free to the public regardless of insurance status.
July 15, Wilkes Early College, 9 a.m. to noon;
July 15, Skyview Center, North Wilkesboro 9-11 a.m. and 4:30-6:30 p.m.
Aug. 2, Wilkes Central High School- 9 a.m. to noon;
Aug. 2, West Wilkes High School- 1-4 p.m.;
Aug. 3, North Wilkes High School, 9 a.m. to noon;
Aug. 3, East Wilkes High School, 1-4 p.m.;
Aug. 5, Wilkes Early College, 9 a.m. to noon;
Aug. 12, St. Paul Episcopal Church, 11:30 a.m. to 1:30 p.m.;
Aug. 21, Rivers Edge Park, Wilkesboro-TBD
Sept. 16-19 at Wilkes Community College during MerleFest
Oct. 2 in downtown North Wilkesboro during the Brushy Mountain Apple Festival. 8 a.m. to 5 p.m.
People interesting in hosting a community vaccine clinic can call 336-651-7450 and ask for Debbie Nicholson or Brandon Call. People who are home bound and wish to be vaccinated can call 336-651-7450 and ask to speak to Debbie Nicholson to arrange this.
Success! An email has been sent to with a link to confirm list signup.
Error! There was an error processing your request.
FROM STAFF REPORTS
All South Carolinians aged 12 and older are eligible to receive the COVID-19 vaccine and can schedule appointments. Currently, Pfizer is the only vaccine available to those aged 12-17. All three vaccines - Pfizer, Moderna and Janssen/J&J - are available to those aged 18 and older.
Visit scdhec.gov/vaxlocator to see the locations accepting vaccination appointments. To register for a DHEC-sponsored clinic, call the vaccine line at 1-866-365-8110 or visit https://cvas.dhec.sc.gov.
Vaccine clinics open for appointments:
Sumter County
- Wednesday-Friday, July 14, 15, 16 - Tandem Health, 370 S. Pike West, Sumter, SC 29150. Make an appointment at https://www.tandemhealthsc.org/covid-19-vaccine/ or call (803) 774-4500.
- Wednesday, July 14 - Sumter County Health Department, 105 N. Magnolia St., Sumter, SC 29150. Open 10 a.m.-2 p.m. Walk-ins welcome. Call 1-866-365-8110 or visit https://cvas.dhec.sc.gov if you prefer to register in advance.
- Thursday, July 15 - Dollar General, 152 W. Willow Grove Road, Lynchburg, SC 29080. Open 9 a.m.-1 p.m., closed noon-12:45 p.m. Walk-ins welcome. First come, first served.
- Friday, July 16 - Ebenezer Community Center, 4580 Queen Chapel Road, Dalzell, SC 29040. Open 10 a.m.-2 p.m. Walk-ins welcome. Call 1-866-365-8110 or visit https://cvas.dhec.sc.gov if you prefer to register in advance.
- Friday, July 16 - Springhill Community Center, 137 Shiver Pond Road, Rembert, SC 29128. Open 9 a.m.-3 p.m., closed noon-12:45 p.m. Walk-ins welcome. First come, first served.
Lee County
- Wednesday, July 14 - Bethlehem United Methodist Church, 115 W. Church St., Bishopville, SC 29010. Open 9 a.m.-3 p.m., closed noon-12:45 p.m. Walk-ins welcome. First come, first served.
- Thursday, July 15 - Lee County Health Department, 810 Brown St., Bishopville, SC 29010. Open 10 a.m.-2 p.m. Walk-ins welcome. Call 1-866-365-8110 or visit https://cvas.dhec.sc.gov if you prefer to register in advance.
TESTING INFORMATION
Free community testing sites for COVID-19 scheduled for this week:
Sumter County
- Central Carolina Technical College, 506 N. Guignard Drive, Sumter, SC 29150
When: 9 a.m.-5 p.m. daily
Sponsored by Tour Health
Go to www.tourhealth.com to schedule an appointment.
County health departments open for testing on weekdays
DHEC-sponsored COVID-19 testing will be open on weekdays at the following locations from 9 a.m. to 3:30 p.m.
- Sumter County Health Department, 105 N. Magnolia St.
- Clarendon County Health Department, 110 E. Boyce St., Manning, SC 29102
- Lee County Health Department, 810 Brown St., Bishopville, SC 29010
Preregistration encouraged; visit https://scdhec.gov/gettested.
Editor's note: This is not an exclusive list and was provided in part by DHEC. Local pharmacies and your physician may also offer both COVID-19 tests and vaccines. For a complete list, call DHEC's vaccine hotline at 1-866-365-8110 or go to https://vaxlocator.dhec.sc.gov/ for an interactive map.
Topics Artificial Intelligence and Business Strategy
The Artificial Intelligence and Business Strategy initiative explores the growing use of artificial intelligence in the business landscape. The exploration looks specifically at how AI is affecting the development and execution of strategy in organizations.
Get updates by email
Please enter a valid email address
Thank you for signing up
Privacy Policy
We tend not to be a company of half measures, notes Dave Johnson, chief data and artificial intelligence officer at Moderna, so when we decide were going to do something, were going to do it. This characterization certainly seems to fit the Cambridge, Massachusetts-based biotech company that made a name for itself in 2020 upon releasing one of the first COVID-19 vaccines approved by the U.S. Food and Drug Administration for emergency use to combat the coronavirus.
Dave Johnson is chief data and artificial intelligence officer at Moderna, where he is responsible for all enterprise data capabilities, including data engineering, data integration, data science, and software engineering. Johnson earned a doctorate in information physics and has more than 15 years of experience in software engineering and data science. He has spent more than a decade working exclusively in enterprise pharma and biotech companies.
In this bonus episode of the Me, Myself, and AI podcast, our hosts learn how Moderna used artificial intelligence to speed up development of the vaccine and how the technology has helped to automate other key systems and processes to build efficiencies across the organization. Dave also describes Modernas digital-first culture and offers insights around collaboration that can be applied across industries.
If youre enjoying the Me, Myself, and AI podcast, continue the conversation with us on LinkedIn. Join the AI for Leaders group today.
Join now
Subscribe to Me, Myself, and AI on Apple Podcasts, Spotify, or Google Podcasts.
Sam Ransbotham: What role did artificial intelligence have in helping combat the coronavirus pandemic? Find out today when we talk with an innovative company that used artificial intelligence to help solve the critical problem society faced in the last year.
Welcome to Me, Myself, and AI, a podcast on artificial intelligence in business. Each episode, we introduce you to someone innovating with AI. Im Sam Ransbotham, professor of information systems at Boston College. Im also the guest editor for the AI and Business Strategy Big Idea program at MIT Sloan Management Review.
Shervin Khodabandeh: And Im Shervin Khodabandeh, senior partner with BCG, and I colead BCGs AI practice in North America. Together, MIT SMR and BCG have been researching AI for five years, interviewing hundreds of practitioners and surveying thousands of companies on what it takes to build and to deploy and scale AI capabilities across the organization and really transform the way organizations operate.
Sam Ransbotham: Today were talking with Dave Johnson, chief data and artificial intelligence officer at Moderna. Dave, thanks for joining us. Welcome.
Dave Johnson: Thanks, guys, for having me.
Sam Ransbotham: Can you describe your current role at Moderna?
Dave Johnson: Im chief data and AI officer at Moderna. In my role, Im responsible for all of our enterprise data functions, from data engineering to data science integration. I also manage the software engineering team building unique custom applications to curate and create new data sets [and] also to then take those AI models that are created and build them into processes. So its kind of end-to-end everything to actually deploy an AI model to build, deploy, and put an AI model into production.
Sam Ransbotham: How did you end up in that role? I know you have physics in your background. I didnt hear any physics in what you just said.
Dave Johnson: Its a good point. So I have my Ph.D. in whats called information physics, which is a field closely related to data science, actually. Its about the foundations of Bayesian statistics and information theory a lot of what is involved in data science. My particular research was in applying that to a framework that derives quantum mechanics from the rules of information theory. So that part, youre right, is not particularly relevant to my day-to-day job. But the information theory part and the Bayesian stats [are] completely on target for what I do. In addition to that, I spent many years doing independent consulting in a software engineering data science capacity. And when I finished my Ph.D., I realized academia wasnt really for me; I wanted to do applications, and I ended up with a consulting firm doing work for large pharmaceutical companies.
So I spent a number of years doing that, and it turned out to be a real great marriage of my skill sets: understanding of science, understanding of data, understanding of software engineering. And so I did one project in particular for a number of years in research at a pharmaceutical company around capturing data in a structured, useful way in the preclinical space in order to feed into advanced data and advanced models so, very much what Im doing today. And about seven years ago, I moved over to Moderna. At the time, we were a preclinical stage company, and the big challenge we had was producing enough small-scale mRNA to run our experiments. And what were really trying to do is accelerate the pace of research so that we can get as many drugs in the clinic as quickly as possible. One of the big bottlenecks was having this mRNA for the scientist to run tests in. So, what we did is we put in place a ton of robotic automation, put in place a lot of digital systems and process automation and AI algorithms as well. And [we] went from maybe about 30 mRNAs manually produced in a given month to a capacity of about a thousand in a month period without significantly more resources and much better consistency in quality and so on. So then, I just kind of from there grew with the company and grew into this role that we have now, where Im applying those same ideas to the broader enterprise.
Shervin Khodabandeh: Thats great, Dave. And can you comment a bit on the spectrum of use cases that AI is being applied to here and is really making a difference?
Dave Johnson: For us, what weve seen a lot of is in the research space particularly. In Moderna, thats been because thats where we digitized early. We see that putting in digital systems and processes to actually capture homogeneous, good data that can feed into that is obviously a really important first step, but it also lays the foundation of processes that are then amenable to these greater degrees of automation. So thats where were seeing a lot of that value, is in this preclinical production we have kind of high throughput, we have lots of data, were able to start automating those steps and judgments that were previously done by humans. One example is our mRNA sequence design. Were coding for some protein, which is an amino acid sequence, but theres a huge degeneracy of potential nucleotide sequences that could code for that, and so starting from an amino acid sequence, you have to figure out whats the ideal way to get there. And so what we have [are] algorithms that can do that translation in an optimal way.
And then we have algorithms that can take one and then optimize it even further to make it better for production or to avoid things that we know are bad for this mRNA in production or for expression. We can integrate those into these live systems that we have, so that scientists just press a button and the work is done for them. And they dont know whats going on behind the scenes, but then poof! out comes this better sequence for them. And then weve seen it with quality-control steps as well.
Were also doing some work right now with our clinical partners in the clinical operation space in terms of optimal trial planning. Were doing some work right now around our call center planning. Now that were rolling our vaccine out across the whole world, more and more phone calls are coming in, and as we look to launching in new countries, we have to start planning our resources for that. Were looking at machine learning models to help predict the forecast of these calls so that we can then staff up appropriately. So we do see it across a variety of different areas.
Sam Ransbotham: You mentioned pressing the button scientists press the button, and some trials happen. What do these scientists think? I mean, youve suddenly taken away something that used to be something that they did, and youre having AI do it. Whats the reaction? Are they thrilled? Are they despondent? Somewhere in between?
Dave Johnson: Id say closer to the thrilled side. Usually how it works were a company that believes in giving people a lot of responsibility, and people work really hard. And what that leads to is people doing a lot of work. And so what often happens is, folks will come to us and say, Look, Im doing this activity over and over. I would really love some help to automate this process. And so, in that case, theyre thrilled. They dont want to be looking at some screen of data over and over and over again. They want to be doing something insightful and creative. And so thats where we really partner with them and take off that component of what they do.
Shervin Khodabandeh: Dave, I want to build on that, because I think youre putting your finger on something quite interesting. In addition to the financial impact that many get from AI, productivity, efficiency, and all of that you talked about some of those, Dave there is an impact in overall organizational culture and teams being more collaborative, higher morale, happier, more confident, etc. Are those some of the things that you guys are seeing as well?
Dave Johnson: For sure. I think one of the sure signs of that is we get a lot of repeat customers. If we do some particular algorithm for somebody, that person comes back with the next one or their team comes back time and time again. We dont think about AI in the context of replacing humans. We always think about it in terms of this human-machine collaboration, because theyre good at different things. Humans are really good at creativity and flexibility and insight, whereas machines are really good at precision and giving the exact same result every single time and doing it at scale and speed. What we find [to be] the most successful projects are where we kind of put the two together have the machine do the parts of the job that its good at [and] let the humans take over for the rest of that.
Sam Ransbotham: With this freedom, what have people done? Youve opened up this time. What kind of new
Shervin Khodabandeh: I got two shots of that, what people have done with that freedom.
Sam Ransbotham: Yeah, actually, theres at least one product thats in the market now, isnt there? I think Ive heard something on the news.
Dave Johnson: Theres one, yeah. You know, I always like to joke that work is like a gas that always expands to fill the container. So if you take something off somebodys plate, theres all this mountain of work that they didnt even realize just wasnt being done. And so people are always relieved to then go on and find the next mountain to climb and the next thing to do.
Sam Ransbotham: But what are these kinds of things? How are people choosing how to expand to fill that space?
Dave Johnson: Well, if you think of the examples like the preclinical quality-control steps that weve automated the reality is, [with] one operator stretched over a huge amount of work, its really hard for them to really do really in-depth inspection of these samples. And so by taking off a bulk of that work 80%, 90%, for the algorithm to do that what theyre able to do is just do a better, more thorough job of inspecting the samples that are left. It also means were not hiring a whole bunch of other people just to go look at screens of data. So its a bit of an immediate gain for the people who are there and then kind of this longer-term gain on our head count plans.
Some folks talk about AI in the pharma space being like, I just want an algorithm that can predict, from the structure of a small molecule, the efficacy in humans, like thats the entire drug discovery process. Thats just not going to happen; thats completely unrealistic. So we just think about the fact that there are countless processes, its a very complicated process to bring something to market, and there are just numerous opportunities along the way. Even within a specific use case, youre rarely using one AI algorithm. Its often, For this part of the problem, I need to use this algorithm, and for this, I need to use another.
Shervin Khodabandeh: Dave, I want to ask you something about the talent base and people. You commented that Moderna is the kind of company that likes to give people a lot of freedom [a] highly motivated, smart, ambitious team working to do the best it can. How do you bring and cultivate that talent, and what are you finding to be some of the lessons learned in terms of how to build a high-performing team?
Dave Johnson: Its a good question. I dont know that if we look across the company as a whole there is one particular place where we hire people. We get people from biotechs, [from] five people to pharmas of 100,000 people and everywhere in between, [from] inside the industry and outside the industry. I think for us, its always about finding the right person for the job, regardless of where they come from and their background. I think the important thing for us is to make sure that we set expectations appropriately as we bring them in, and we say, Look, this is a digital company. Were really bold. Were really ambitious. We have really high quality standards. And if we set those expectations really high, it does start to self-select a lot of the people who want to come through that process.
Sam Ransbotham: I want to flip over and talk You mentioned some of the infrastructure, I would call it, that you put in place that suddenly the world benefited from a few months ago. How did people know to get those things set up in the first place? You mentioned being able to scale from, I think, 30 to a thousand different How did you know that was the direction, or that was the vision to get those things set up?
Dave Johnson: Thats a great point. The whole COVID vaccine development, were immensely proud of the work that weve done there, and were immensely proud of the superhuman effort that our people went through to bring it to market so quickly. But a lot of it was built on just what you said: this infrastructure that we had put in place where we didnt build algorithms specifically for COVID; we just put them through the same pipeline of activity that weve been doing. We just turned it as fast as we could. When we think about everything we do at Moderna, we think about this platform capability. We were never going to make one drug; that was never the plan. The plan was always to make a whole platform around mRNA because, since its an information-based product, all you do is change the information encoded in the molecule, and you have a completely different drug. We knew that if you can get one in the market, you can get any number of them to the market. And so all the decisions we made around how we designed the company and how we designed the digital infrastructure was all around this platform notion that were not going to build this for one thing were going to build a solution that services this whole platform. And so thats exactly why we built this early preclinical staff where we can just crank through quite a few of these. Thats why we built these algorithms to automate activities. Anytime we see something where we know that scale and making it parallel is going to improve things, we put in place this process.
Sam Ransbotham: The proof is certainly in the pudding. One thing that Im kind of finding fascinating is how normal this all is. I guess Im just surprised at how much that seems to be part of your Can I use the word DNA here?
Dave Johnson: Its totally fine.
Sam Ransbotham: RNA.
Shervin Khodabandeh: mRNA. Its part of their mRna.
Dave Johnson: Yeah, no, its true. We were founded as a digital biotech and a lot of companies say things and put taglines on stuff, but we really meant it. And we have pushed on this for many years, and weve built out this for many years.
Shervin Khodabandeh: Its the platform you built, and now its running.
Dave Johnson: Its the platform approach we take to our data science and AI projects as well. I hear a lot of struggles from folks around, Great, I built a model and a Jupiter notebook. Now what do I do with it? As they resolve this data cleansing and data curation to even get it to be in a useful state, then they dont know where to go from it to deploy it. And we took the same platform approach to our data science activities. We spent a lot of time on the data curation, data ingestion, to make sure the data is good to be used right away. And then we put a lot of tooling and infrastructure in place to get those models into production and integrated. So this platform mentality is just so ingrained into how we think.
Sam Ransbotham: Take us back to early in the COVID race for a vaccine. What was it like being part of that team and a part of that process? I mean, what were the emotions like when the algorithms or when the people find something that seems to work or that seems promising? Does that lead to a massive appetite for more artificial intelligence and more algorithms? Tell us a little bit about that story.
Dave Johnson: I think if you look at how people felt in general at the time, it was a real sense of honor and pride. We felt very uniquely positioned. Wed spent a decade getting to this point and putting all of this infrastructure in place and putting things in the clinic before this to get to this moment. And so we just really felt truly honored to be in that position. And for those of us on the digital side who have kind of contributed to this and built it, this is why we did it. This is why were here: to help bring as many patients [these vaccines] as quickly and safely as possible [throughout] the world. But there was always the question of, Would this thing work in the real world? And thats where the proof came in the clinical data, and we were all anxiously waiting like everybody else to see that readout.
Shervin Khodabandeh: Was AI always front and center at Moderna, or has it become more critical as a pillar of growth and innovation over time?
Dave Johnson: I think its always been there, though we probably didnt call it that in the early days; its become obviously much more of a hot marketing term than it used to be. But the notion of algorithms taking over decision-making and data science capability was absolutely always there. We were very thoughtful about how we built this digital landscape, such that were collecting structured data across all these steps, knowing full well that what we want to do is then turn those into algorithms to do things. So it was very purposeful for that. But I do think its also come into a greater focus because weve seen the power of it very recently, obviously. Weve seen how this digital infrastructure and how these algorithms can really help push things forward. And so its gotten that kind of a renewed focus and importance in the company.
We tend not to be a company of half measures, so when we decide were going to do something, were going to do it. Its been a very strong message from our senior leadership, about This is the future of the company injecting digital and AI into everything we do. Under no uncertain terms, this is happening. To the point that, as we think about the fact that were growing really fast as a company we just doubled; were probably going to double again were bringing in a lot of new folks from outside the company, to grow, who are not necessarily familiar with this digital culture that weve had. And so, what were working on right now is actually developing what were calling an AI academy, which we intend to be a very thorough, in-depth training for our company, from people who would use and interact with AI models on a daily basis to senior leaders who would be responsible [for] a portfolio of potential projects in their areas. And that just shows the level of serious commitment we have about this. We were built on this concept of having a smaller company thats very agile and can move fast. We see digital as a key enabler for that and AI as a key enabler for that. So the hope is that helps us to compete in ways that other companies cant. And that is certainly the intention here.
Sam Ransbotham: Dave, thanks so much for talking with us today. We really enjoyed I mean, you mentioned Moderna hires smart people, and we know that from a sample size of one thats clearly true. Thanks for taking the time to talk with us today.
Shervin Khodabandeh: Thank you so much.
Dave Johnson: Absolutely, guys. I really appreciate it.
Shervin Khodabandeh: Sam, that was an awesome conversation with Dave. What do you think?
Sam Ransbotham: Impressive. Im glad hes around. Im glad Moderna is around.
Shervin Khodabandeh: Thats right.
Sam Ransbotham: This is real.
Shervin Khodabandeh: Hes not paying lip service to buzzwords and this, that, and the other. Hes just, Yeah, we started this way. Thats why were doing it. We would not have existed without digital and AI and data and analytics. Of course its real. Thats where we are. He said Moderna is a digital company. Thats what he said.
Sam Ransbotham: Its just part of their process. Some of the questions, it didnt even occur to him that it was artificial intelligence; thats just the way they do things. I wonder if thats the new industry after industry, are we going to see the Moderna-type approaches come into industries and just be dominant? The vestiges of historical Oh, weve been around for 100 years are almost a liability versus a plus.
Shervin Khodabandeh: I think this contrast, Sam, that you were trying to get at, which is, How come its so easy for you guys, and what about the pre/post and the transformation? Hes like, Well, we actually started this way. We said we wanted to be a small company.
Sam Ransbotham: They started post.
Shervin Khodabandeh: Yeah, We started post. We wanted to be agile, we wanted to be small, we wanted to do a lot more with everything that we had, and so that had to be platform-centric, data-centric, AI-centric, and thats how we built [the company]. So AI is everywhere. Why are you surprised, Sam, that AI is everywhere? Of course, its everywhere. We do it for planning and the trials and sequencing and Its quite energizing and intriguing how its just a very different mindset toward AI.
Sam Ransbotham: Right. And I know that we dont want to make everything AI. Theres a lot thats going on there thats not artificial intelligence, so I dont want to paint it as entirely [AI], but that certainly was a big chunk of the speed story here, and its pretty fascinating.
Allison Ryder: Thanks for joining us for this bonus episode of Me, Myself, and AI. Well be back in the fall with new episodes for Season 3. In the meantime, stay in touch with us on LinkedIn. Weve created a group called AI for Leaders specifically for audience members like you. You can catch up on back episodes of the show, meet show creators and hosts, tell us what you want to hear about in Season 3, and discuss key issues about AI implementation with other like-minded people. Find the group at https://mitsmr.com/AIforLeaders, which will redirect you to LinkedIn, where you can request to join. Well put that link in the show notes as well, and we hope to see you there.
Sam Ransbotham (@ransbotham) is a professor in the information systems department at the Carroll School of Management at Boston College, as well as guest editor for MIT Sloan Management Reviews Artificial Intelligence and Business Strategy Big Ideas initiative. Shervin Khodabandeh is a senior partner and managing director at BCG and the coleader of BCG GAMMA (BCGs AI practice) in North America. He can be contacted at shervin@bcg.com.
Me, Myself, and AI is a collaborative podcast from MIT Sloan Management Review and Boston Consulting Group and is hosted by Sam Ransbotham and Shervin Khodabandeh. Our engineer is David Lishansky, and the coordinating producers are Allison Ryder and Sophie Rdinger.
The City of Columbia is partnering with Prisma Health for a free COVID-19 vaccine clinic Friday.Courtesy: City of Columbia
COLUMBIA, SC (WOLO) Weve told you about the City of Columbias effort to get more South Carolinians vaccinated by offering free flights with American Airlines. If want your chance to win, one of those free vaccination events is coming up this week.
Prisma Health will have a vaccination clinic at the Drew Wellness Center on 2101 Walker Soloman Way on Friday from 1-4 p.m. The Pfizer vaccine will be available to everyone ages 12 and older.
Anyone who gets vaccinated at this site will be entered to win two free round trip tickets from American Airlines. The winner will be randomly selected by a drawing at a date to be announced in August.
